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ABSTRACT 
Trans-Resveratrol (RV) is a natural polyphenol characterized by interesting pleiotropic 
potentials and health benefits, but its administration is hampered by a unsatisfactory 
pharmacokinetics. Various approaches have been identified to circumvent it: among 
them, 2-hydroxypropyl-β-cyclodextrins (HPβCD) are valuable strategy. Here, we 
compare the employment of HPβCD based formulation with a resveratrol 
nanosupension (obtained by diluting a RV ethanol solution with PBS, added of 0.05 % 
hydroxyethylcellulose) to improve RV bioavailability after oral administration to mice. 
The inclusion of RV in HPβCD was confirmed by differential scanning calorimetry, 
Fourier transformed infrared spectroscopy, and phase solubility study. The two 
formulations were orally administered to BALB-c mice. RV concentrations in plasma 
and tissues were detected at different time (0-120 min) by HPLC method. HPβCD 
complexation mediate a ~4-fold increment in plasma RV Cmax and ~2-fold augment of 
RV AUC0-120 in comparison with RV nanosuspension. Similar increased concentrations 
were observed in heart, liver, kidney and gut. In particular, HPβCD mediated a 
5.5-folds increase of resveratrol concentration in the intestine, in comparison to the 
nanosuspension.  
In conclusion, based on our results, HPβCD complexation is a promising approach to 
increase the oral bioavailability of RV. Moreover, the achievement of high 
concentrations in gut suggested a potential employment of oral RV-HPβCD as 
anti-inflammatory/chemopreventive agent in this tissue. 
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Introduction 
 
A great number of natural molecules were identified and characterized for their 
utilization in human disorders. Although they displayed strong in vitro activities, the 
unfavorable physical/chemical properties frequently limited their clinical utilization 
[1]. Among others, trans-resveratrol (RV, 3,5,4’-trihydroxy-trans-stilbene) is one of 
the most studied natural polyphenols. It is a phytoalexin synthesized by various 
plants in response to stress and microbial attack. Moreover, it shows interesting in 
vitro pleiotropic effects, including anti-oxidant, anti-aging, anti-inflammatory, and 
anti-cancer actions as well as neuro- and cardiovascular protection [2,3]. However, 
the systemic administration of RV is hampered by its low water solubility, low 
stability (mainly linked to inactivation by trans-to-cis isomerization in solution) and 
rapid extensive in vivo metabolism [4], which together impair the achievement and 
the maintenance of bioefficacious concentrations in the blood and target tissues 
[5,6]. Thus, the limited amount of intact RV existed in the systemic circulation could 
not guarantee therapeutic concentration, producing uncertain in vivo results, as 
already reviewed by Carter et al. [7].  
Various approaches have been identified to circumvent these problems, some of 
which are nowadays in clinical experimentation [8-10]. Among them, cyclodextrins 
(CDs) have displayed a considerable ability to include and protect natural 
compounds [11,12]. CDs are a family of cyclic oligosaccharides made up of variable 
glucose residues linked by glycosidic bonds; furthermore, they consist of a truncated 
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cone structure with a hydrophobic cavity, which could form inclusion complexes with 
a wide range of guest molecules, modifying their physical and chemical properties. In 
particular, 2-hydroxypropyl-β-CD (HPβCD), a semisynthetic CD, demonstrated to 
possess high molecular recognition and inclusion ability as well as to improve 
water-solubility of natural molecules, including RV [13]. In this context, the 
complexation with HPβCD has been already employed to reduce the trans-to-cis 
isomerization rate of resveratrol, thus enhancing its molecular stability [14].  
The aim of our study was to investigate improvements that HPβCD complexation 
should induce to RV pharmacokinetics. In particular, in a mouse model we evaluated 
and compared RV bioavailability and concentration in different tissues after the oral 
administration of a single dose of RV, which was formulated as complex in HPβCD 
(RV-HPβCD) or as aqueous nanosuspension in water (RV-ns). 
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Materials and methods 
 
Materials 
Trans-resveratrol (RV) was purchased from Cayman Chemical (Ann Arbor, MI, USA); 
HPβCD (KLEPTOSE® HPB ORAL GRADE MEDIUM MS, DS 4.5, average MW 1399.35) 
was kindly gifted by Roquette (Lestrem, France). Hydroxyethylcellulose was from 
A.C.E.F. (Piacenza, Italy); HPLC grade acetonitrile was from VWR International PBI 
(Milan, Italy); HPLC grade water was produced with Milli DI system coupled with a 
Synergy 185 system by Millipore (Milan, Italy); HPLC grade methanol and acetic acid 
were from Sigma-Aldrich (St. Louis, MO, USA), as well as all the other analytical grade 
reagents. 
 
HPLC determination of trans-resveratrol 
For HPLC determination of trans-resveratrol a Lachrom7000 HPLC (Merck–Hitachi, 
Merck KGaA, Darmstadt, Germany) equipped with a C18 analytical column 250×4.6 
mm, 5 μm (Alltech Italia S.r.l., Milano, Italy) preceded by a guard column (C18 
SecurityGuard Cartridges 4.0x3.0, Phenomenex, Castel Maggiore, Italy) was used. The 
mobile phase consisted of a gradient of 0.5% acetic acid, methanol, and acetonitrile 
(0–5 min: 52:48:0, v/v/v; 6–19 min: 52:10:38, v/v/v; 20–21 min: 52:48:0, v/v/v) at 
the constant flow rate of 1 ml/min at 30° C. Sample elution was monitored at the 
303 nm wavelength.  
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Preparation of the resveratrol formulations 
To prepare the HPβCD complex, RV was finely suspended in a water solution 
containing an equimolar amount of HPβCD and the suspension was stirred at room 
temperature in the dark until the equilibrium was reached (24 h)[14]. After 
centrifugation, the supernatant was freeze-dried. To determine the RV percentage in 
the complex, a weighted amount of obtained freeze-dried inclusion complex 
(RV-HPβCD) was dissolved in methanol. After sonication, the sample was diluted with 
methanol and analyzed by HPLC for a quantitative determination of RV. As stock 
solution, freeze-dried RV-HPβCD complex was dissolved at the concentration 
equivalent to 7 mM RV in PBS, pH 7.4.  
To prepare the nanosuspension a two-step process was employed. Firstly, an 
ethanolic solution of RV was prepared at the concentration of 200 mM. Then, the RV 
nanosuspension (RV-ns) was obtained, diluting with PBS the ethanolic solution, to 
reach the same final molar concentration of RV-HPβCD complex. As the dilution 
causes a rapid precipitation of RV, the nanosuspension was stabilized by the addition 
of hydroxyethylcellulose (0.05 % w/w). 
 
Phase solubility studies 
Phase solubility studies were carried out according to the Higuchi-Connors method 
[15]. An excess of RV (5 mg) was added to a series of aqueous solutions (5 ml) 
containing increasing concentrations of HPβCD from 0 to 5 mg/ml (3.24 mM). The 
samples were shaken in the dark at room temperature for 24 h. After equilibration, 
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suspensions were centrifuged and quantitative determination of RV in the 
supernatant was carried out by HPLC method. The phase diagram was constructed by 
plotting the total molar concentration of RV in solution against the molar 
concentration of HPβCD. 
Stability constants (Kst) from the phase solubility diagram was calculated according to 
the formula #1 (F1):  
F1: 
 
where S0 represents the intrinsic solubility of RV in absence of HPβCD. The slope was 
determined from the initial straight-line portion of the plot of concentration of RV 
against the concentration of CDs. 
The complexation efficiency (CE), defined as the concentration ratio between 
cyclodextrin in a complex and free cyclodextrin, is calculated from the 
phase-solubility diagrams, with the formula #2 (F2): 
F2: . 
 
In vitro solubility studies 
In vitro experiments were conducted by dialysis bag technique to evaluate the 
solubility kinetics of the RV-ns. The analysis was carried out at 37 °C. A cellulose 
membrane (Spectrapore, cut-off 12000 Da) separates the donor compartment 
containing 15 mg/ml of RV-ns from the receiving compartment filled with filtered 
water and 0.05% sodium dodecyl sulfate (SDS) as dissolution medium, to maintain 
sink conditions. The receiving phases were withdrawn at regular intervals and 
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replaced with the same amount of fresh receiving medium; quantitative 
determination of RV was carried out by a HPLC method. Data were expressed as 
percentage of RV dissolved over time. 
 
Characterization of the resveratrol formulations 
The analysis of RV-ns particle size was performed by photoncorrelation spectroscopy 
using a 90 Plus instrument (Brookhaven, NY, USA), at a scattering angle of 90° and a 
temperature of 25 °C, after an opportune dilution of the nanosuspension with 
deionized water. 
Differential scanning calorimetry analysis (DSC) was carried out using a DSC/7 
differential scanning calorimeter (Perkin-Elmer, Branford, CT, USA) equipped with a 
TAC 7/DX instrument controller. The instrument was calibrated with indium for 
melting point and heat of fusion before analyses took place. A heating rate of 10°C 
per minute was used in the 25-290 °C temperature range. The thermal behavior was 
studied by heating about 3 mg of RV and freeze-dried RV-ns and RV-HPβCD in 
standard aluminum sample pans (Perkin-Elmer); an empty aluminum pan was used 
as the reference standard. Analyses were carried out under nitrogen purge; analyses 
were performed in triplicate for each sample. 
RV, HPβCD, and RV-HPβCD underwent to Fourier transformed infrared spectroscopy 
(FTIR) studies by potassium bromide disc method using Perkin Elmer system 2000 
FTIR Spectrophotometer in the region of 4000-450 cm-1. 
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In vivo pharmacokinetics assessment  
Pharmacokinetics profile was evaluated on seventy-five two-month old BALB-c mice 
from the animal facility of Molecular Biotechnology Center (University of Turin). 
Animals were fed ad libitum, but starved the night before the experiment.  
Forty-eight mice received oral administration of either RV-ns or RV-HPβCD (n=24 
each group) by orogastric tube. After administration, each mouse had received a 
single dose equivalent to 15 mg/kg RV. Three mice per group were bled and then 
euthanized at 1, 2, 5, 10, 15, 30, 60 and 120 minutes. Blood samples were collected 
and immediately centrifuged at 3000 rpm, 4°C for 10 minutes to obtain plasma. Brain, 
heart, liver, kidney, and gut were explanted, rinsed in saline, and frozen in liquid 
nitrogen for further HPLC analysis. 
To calculate and compare bioavailability of RV formulations, 27 mice were 
administered with RV-ns (equivalent to 15 mg/kg RV) by tail vein injection; 3 mice 
were bled immediately after the RV injection or at 1, 2, 5, 10, 15, 30, 60 and 120 
minutes. All blood samples were processed as above described.  
Bioavailability was evaluated in collected bloods through the employment of the 
formula #3 (F3): 
F3:  
Where AUC (Area Under Curve) represents the concentration-time profile, and D 
represents the administered dose for both per os (po) and intravenous (iv) 
administrations. 
All procedures for the animal care and treatment were in accordance with the 
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Institutional and National Animal Care Committees. 
 
Resveratrol extraction 
Plasma samples were supplemented with 1.5-folds of extraction solution 
(methanol/2.5% acetic acid solution 90:10 v/v containing 0.05% of ascorbic acid), 
containing 2 μg/ml flavon (as internal standard, IS). Samples were centrifuged at 
2000 rpm at 4°C for 3 minutes and supernatants were collected. Tissues were 
processed as follows: 100 mg of each organ were homogenized in 3ml of extraction 
solution for 3 minutes by means of an ULTRA TURRAX (T25, IKA, Germany), added of 
2 μg/g IS and processed as described above. Obtained pellets were re-extracted with 
the same procedure. The two corresponding supernatants were unified and 
freeze-dried. For each passage, samples were kept on ice and protected from light. 
Blank tissues added with different RV concentrations were processed as described 
above in order to obtain calibration curves for each organ in the subsequent 
analyses. 
 
Resveratrol quantification 
Dried samples were reconstituted with 300 μl of the starting composition of the 
mobile phase (0.5% acetic acid/methanol 52:48 v/v) and centrifuged. Fifty microliters 
of each supernatant was collected and analysed by means of a Lachrom7000 HPLC 
(Merck–Hitachi, Merck KGaA, Darmstadt, Germany) as described above. 
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Statistical analysis 
The calibration curves for HPLC analyses were constructed by plotting the 
peak-height ratios of RV to IS versus the nominal concentrations in the standard 
biological samples using linear regression analysis. 
RV concentrations were represented as mean ± standard error of the mean (SEM). 
The maximum reached concentration (Cmax), the time needed to reach the Cmax (Tmax), 
and concentration-time profile (AUC) were calculated with PKSolver v2.0. 
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Results 
Phase solubility studies 
The RV solubility increased as a function of HPβCD concentration as reported in Fig. 
1A. An “A-type” diagram was obtained, according to the Higuchi and Connors 
classification [15], where the guest solubility increased linearly with HPβCD 
concentration. The calculated stability constant (Kst) was 6960 M-1. The slope of the 
curve was lower than one, thus it was assumed that the gain in solubility observed 
was due to the formation of a 1:1 complex. In fact, the calculated complexation 
efficiency (CE) was 1.11. 
 
Characterization of resveratrol formulations 
As demonstrated by photon-correlation spectroscopy, the average diameter of RV 
nanoparticle in the RV-ns was about 800 nm. Furthermore, both RV-ns and RV-HPβCD 
formulations induces alteration in the thermogram of RV (Fig. 1B). In fact, a shift of 
the 267 °C melting endothermic peak of RV toward cooler temperatures 
accompanied by a reduction in endothermic energy was observed in RV-ns, due to 
the stabilization induced by the hydroxyethylcellulose. Meanwhile in RV-HPβCD, the 
endothermic peak was absent, indicating the interaction between RV and HPβCD and 
the formation of inclusion complexes. In this context, RV is molecularly dispersed in 
the cyclodextrin cavity without the possibility to crystallize. In addition, the 
characteristic infrared absorption of C-C aromatic double bond stretching founding in 
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the spectrum of RV in the range of 1700-450 cm-1 was altered in RV-HPβCD (Fig. 1C). 
The shifted spectral features of guest molecule in RV-HPβCD complex confirmed the 
inclusion of RV in the HPβCD cavity. Finally, RV-ns required 6 hours to be dissolved 
quite completely (about 95%) in water. Figure 1D reports the in vitro solubility 
kinetics of RV from RV nanosuspension. 
 
HPLC method results  
The specificity of HPLC method was determined by comparing the chromatograms of 
blank plasma/tissue with the corresponding spiked plasma/tissue. RV and IS were 
eluted approximately at 6.4 and 19.0 min, respectively (Fig. 2). Data from calibration 
curves were reported in Table 1. 
 
Quantitation of resveratrol in plasma after single oral administration 
The concentration of RV in plasma was determined by HPLC. The mean plasma 
concentration-time profiles after single administration of RV-ns (per os and 
intravenous) and RV-HPβCD (per os) are shown in Table 2, whereas the corresponding 
pharmacokinetic parameters are reported in Table 3. 
Cmax of RV-HPβCD was 3.94-folds than RV-ns, while the AUC0-120 was 2.04 folds greater. 
Consequently, oral bioavailability of the two RV formulations was 52.5% and 25.8%, 
respectively. Curve profiles of oral administered formulations showed peaks of 
concentration at 5 and 30 minutes for HPβCD and RV respectively. After intravenous 
administration the RV plasmatic concentration reaches about 100 g/ml and tends to 
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zero after 30 minutes, with a T1/2 of ~10.34 min. 
 
Tissue distribution of resveratrol  
The detection of RV concentrations in brain, heart, liver, kidney, and gut was 
performed as previously described for plasma samples. The tissue 
concentration-time profiles of orally administered RV-ns and RV-HPβCD are shown in 
Fig. 3A. Similarly to what occurs in plasma, the complexation in HPβCD significantly 
improve the RV Cmax and AUC1-120 in all considered organs, at exclusion of brain where 
RV was detected in concentrations ten-fold smaller than other tissues (Fig. 3B-3C). 
Interestingly, a great amount of RV was detected in gut where HPβCD was able to 
mediate a 5.5-fold increase of AUC1-120. This is due to the presence of a great peak of 
concentration at 30 minutes from the administration that is not detectable in RV-ns 
profile.  
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DISCUSSION 
 
Researchers’ trays are full of unfulfilled dreams: in particular, those of chemists and 
pharmacologists contain a large number of molecules, often of natural origin, which 
are characterized by interesting beneficial effects, but not clinically employable due 
to poor pharmacokinetics (poor water solubility, rapid metabolism, etc.).  
Resveratrol was discovered in 1940 [16], but its first beneficial effect was detected in 
1992 [17] when RV has been postulated to explain some of the cardio-protective 
effects of red wine. From then, RV has been extensively studied and, though the 
exact molecular mechanisms are currently still unclear, a broad-spectrum of 
beneficial health properties has been shown, such as anti-infective (anti-bacterial, 
anti-fungal, anti-malarial, and anti-viral), anti-oxidant, anti-inflammatory, anti-allergic 
(immune regulation), and anti-diabetic (it enhances insulin sensitivity) actions [18,19]. 
Moreover, Jang and colleagues [20] firstly reported in 1997 the RV-mediated 
chemoprevention through the inhibition of cyclooxygenase activities. Likewise, other 
anticancer related mechanisms were soon revealed, and RV-mediated inhibition of 
ribonucleotide reductase [21], DNA polymerase [22], cell cycle progression [23] as 
well as the targeting of ornithine decarboxylase [24], PTEN/Akt [25], NFkB [26], and 
STAT3 [27] have been reported.  
The main obstacle to the clinical RV employment resides in its poor aqueous 
solubility and bioavailability, which greatly hampers its efficacy after oral 
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administration [28]. In deep, based on the urinary excretion data in humans, the 
absorption of RV appears to be at least 70% [6,29]. Also in rats, after oral 
administration, RV intestinal absorption was elevated (about 77–80%) [30]. However, 
due to rapid and extensive metabolism, RV has a very short initial half-life that was 
approximately calculated in 8-14 minutes [31]. Consequently, circulating RV is rapidly 
inactivated and removed from the body [32], resulting in only trace amounts of 
unchanged molecules in the systemic circulation. Hence, circulating RV is unlikely 
able to achieve 1.14 mg/L (5 µM) in plasma, which is postulated as a minimum 
effective chemoprevention concentration to guarantee its therapeutic activities [29]. 
Beyond these important shortcomings, several research groups threw light on the 
complex RV metabolic pattern identifying precursors to be employed as pro-drugs [5] 
and several different metabolites (e.g. sulfated and glucuronide), some of which still 
retain the RV activities [29,33]. On these bases and to improve kinetics and biological 
efficacy, several RV analogues were thus synthetized, allowing to the findings that 
poly-hydroxylated RV derivatives showed high rate of COX inhibition, free radical 
scavenging activity and ribonucleotide reductase inhibition.  
Another strategy to circumvent the poor pharmacokinetics of RV and achieve 
therapeutic doses after oral administration is the possibility to formulate RV to 
protect it from metabolism and elimination. Focusing the attention on CDs, they have 
been shown to enhance drug bioavailability through stabilization of drug molecules 
that have low aqueous solubility but show good membrane permeability [34], such 
as resveratrol. Furthermore, hydrophilic CDs, e.g. HPβCD, are able to increase 
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permeation of lipophilic drugs. In this context, we already reported that the 
complexation of RV in HPβCD was able to mediate a chemo-preventive action in an in 
vivo model of chemically induced oral squamous cell carcinoma, even though after 
topic application on buccal mucosae [35]. In addition, RV complexation with either 
HPβCD or random-methyl-βCD improved the water solubility of RV, though data 
about oral administration were limited only to random-methyl-βCD [36,37]. 
The effect of the complexation of trans-resveratrol with HPβCD on its biological 
properties was largely investigated [38]. The antioxidant activity of RV in the absence 
and presence of increasing concentrations of HPβCDs was determined by 
Lucas-Abellan et al. [39] showing that complexation led to an increase not only in its 
aqueous solubility but also in its antioxidant activity. On the contrary, other authors 
[13] reported that the differences in scavenging capacity between free and 
complexed resveratrol are slight, suggesting that the inclusion process had little 
influence on the antioxidant activity. Moreover, Sapino et al. demonstrated that the 
inclusion phenomenon did not significatively interfere with the radical scavenging 
activity, the metal-chelating efficiency and the antilipoperoxidative potential of 
resveratrol [14]. 
In the light of these premises, we evaluated the HPβCD complex as strategy for the 
oral administration of RV, inasmuch as orally administered HPβCD (up to 500 
mg/kg/day [40]) is non-toxic likely due to their low absorption (2–4%) along the 
gastrointestinal tract [41]. Moreover, also RV displays a good safety profile: in vivo 
study demonstrated that RV toxicity occurs at high dose, only. Indeed, as reviewed by 
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Cottart et al [42], RV is safe in the animal until the dose of 3g/kg/day, which 
corresponds to 210 g/day in humans. At this concentration, 2 of 40 rats (5%) died 
after being treated continuously for 4 weeks.  
In this study, we confirmed that RV is able to interact with and to be included within 
HPβCD cavity to form an inclusion complex in the 1:1 ratio as evinced by the direct 
correlation between RV aqueous solubility and HPβCD concentration in the 
phase-solubility study, likewise what already reported by Das et al [36] and Duarte et 
al [37]. In fact, they both demonstrated “A-type” phase solubility diagrams 
characterized by the formation of 1:1 ratio moderately stable complexes with either 
HPβCD or random-methyl-βCD.  
Obtained inclusion complexes are noteworthy able to mediate, in vitro, a higher and 
faster diffusion through membranes with respect to the free drug. Motivated by this 
result, we thus assessed the in vivo systemic pharmacokinetics of RV comparing the 
results of the nanosuspension with those of HPβCD complexes. To our best 
knowledge, this is the first work that investigated the tissue distribution of RV after 
oral administration of RV-HPβCD complex. 
Results agreed with those obtained in vitro and indicated a general improvement of 
RV in analyzed tissues, which was reflected in an improved oral bioavailability and 
kinetics of RV-HPβCD when compared with unvehicled RV. The plasma 
pharmacokinetics is in agreement with previous findings. Das and coworkers [36] 
studied the pharmacokinetics of RV-HPβCD complex after the intravenous 
administration at different doses. The complexation with HPβCD did not marked 
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affect the blood circulation time. Indeed, the dissociation of included molecule from 
the cyclodextrin complexes occurs after the blood dilution, determining a rapid 
release of the drug. Interestingly, in our study, HPβCD complexation enabled RV to 
reach the minimum chemoprevention concentration in plasma within the first ten 
minutes after oral administration of a single dose of RV-HPβCD complex. This effect 
may be likely owing to the increased stability, water solubility and permeation 
through membranes demonstrated by HPβCD complex [43]. Besides this initial 
response, a second peak was detected in plasma after thirty minutes from the 
administration. It is noteworthy that, in this case, high amounts of RV were also 
detectable concomitantly in the gut. This type of kinetics is consistent with the 
enterohepatic recirculation already reported by other Authors and likely due to 
glucuronated metabolites that are reconverted in RV by the intestinal flora [44]. The 
phenomenon, together with the in vitro enhancement of permeation through the 
membranes, can explain the great amount of RV detectable even after one hour in 
kidney, which is the main elimination route of RV in the organisms [44]. HPβCD 
complexation was not able to allow RV to pass the hematoencephalic barrier: as a 
result, only trace of RV was found in brain.  
Anyway, it has been demonstrated that changing the formulation employed to 
vehiculate the drug, its pharmacokinetics can consequently change: indeed, utilizing 
a similar approach, but exploiting lipophilic vectors (solid lipid nanoparticle), Jose 
and co-workers were able to specifically enhance the brain delivery of RV [45]. 
The development of new formulations can make an old drug suitable for a new 
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medicinal product registration. The use of CDs as excipients allows the achievement 
of a formulation ready for clinical trials. HPβCD is an excipient admitted by 
Regulatory Authorities for oral and intravenous administration and its monography is 
reported in the European Pharmacopoeia. A number of medicinal products 
containing HPβCD are already on the market. Here, we demostrated in our 
knowledge for the first time that RV can be efficaciously delivered in vivo with 
non-expensive and safe carriers represented by cyclodextrins. In fact, we showed 
that RV-HPβCD complexes greatly enhanced the oral bioavailability of RV (more than 
twice with respect to RV aqueous nanosuspension). Despite we analyzed the 
pharmacokinetics after a single dose administration only, our formulation was able 
to reach bioactive concentrations in both plasma and gut. In particular, considering 
the time and concentration profile of RV detected in the latter, RV-HPβCD complexes 
could become a promising tool to address chronic inflammatory and/or 
precancerous lesion of gut, thus the efficacy of chronically administered RV-HPβCD 
complexes are under investigations. 
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CAPTIONS 
 
 
Fig. 1. Characterization of RV-HPβCD inclusion complex. Solubility of RV improves at 
the increasing concentration of HPβCD (A); Differential Scanning Calorimetry (DSC) 
thermograms of RV, RV-ns and RV-HPβCD (B); and FTIR spectra of RV and RV-HPβCD 
(C); In vitro solubility kinetics of 15 mg/ml RV nanosuspension (D).  
 
Fig. 2. Representative chromatograms of blank plasma (A), blank plasma spiked with 
2μg/ml RV (B) and plasma sample obtained at 30 min after oral administration of 
15mg/kg RV-ns (C). Peak 1, RV; peak 2, IS (flavone). 
 
 
Fig. 3. Pharmacokinetics of RV in tissues. RV concentrations are detected after oral 
administration of 15mg/kg RV-HPβCD or RV aqueous nanosuspension (RV-ns) in brain, 
heart, liver, kidney and gut (A). Values are represented as means±SEM. CMAX (B) and 
AUC0-120 (C) of the different tissues are shown. 
 



Table 1 Calibration curves 
* = μg/ml 
Biological sample Calibration curve Linear range 
(RV/sample, μg/g)  
Correlation 
coefficients (r) 
Plasma Y=1.942X-0.0132 0.015625-2.0 * 0.9967 
Brain Y=1.689X 0.0625-2.0 0.9967 
Heart Y=1.844X+0.1391 0.125-2.0  0.9943 
Liver Y=1.998X 0.125-2.0  0.9997 
Kidney Y=1.986X+0.1349 0.0625-2.0  0.9969 
Gut Y=1.021X 0.03125-8.0  0.9995 
Table 2: Plasma concentration-time profiles after administration of 15mg/kg 
RV-ns and RV-HPβCD 
 
Time (min) 
i.v. per os 
RV-ns (µg/ml) RV-ns (µg/ml) RV-HPβCD (µg/ml) 
0 119.13 ± 6.38 - - - - 
1 19.92 ± 0.49 0.28 ± 0.14 2.26 ± 0.50 
2 14.67 ± 2.29 0.26 ± 0.06 2.62 ± 1.76 
5 5.25 ± 0.75 0.60 ± 0.16 3.35 ± 1.44 
10 1.78 ± 0.18 0.10 ± 0.05 1.53 ± 0.61 
15 0.77 ± 0.13 0.58 ± 0.20 0.50 ± 0.31 
30 0.07 ± 0.01 0.85 ± 0.33 1.60 ± 0.47 
60 0.02 ± 0.01 0.15 ± 0.12 0.17 ± 0.08 
120 0.01 ± 0.01 0.09 ± 0.02 0.19 ± 0.05 
Concentrations are represented as means ± SEM 
 
Table 3 Pharmacokinetic parameters in plasma 
 
 
 
 
 
 
TMAX : time to maximum plasma concentration 
CMAX: the maximum plasma concentration. 
AUC0–120: the area under plasma concentration—time curve to 120 minutes. 
 
Route Formulation TMAX 
(min) 
CMAX  
(μg/ml) 
AUC0-120 
(μg/ml*min) 
Intravenous RV-ns 0 119.13 149.30 
Oral RV-ns 30 0.85 38.46 
Oral RV-HPβCD 5 3.35 78.38 
